SUNPHARMA:NSE:NSE-Sun Pharmaceutical Industries Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1866.1

Change

+3.15 (+0.17)%

Market Cap

USD 4,371.22B

Volume

0.74M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

+16.95 (+0.31%)

USD 1,451.89B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-93.65 (-2.71%)

USD 1,161.24B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-31.00 (-2.79%)

USD 1,125.52B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-63.85 (-0.96%)

USD 1,094.10B
LUPIN:NSE Lupin Limited

-45.45 (-2.00%)

USD 1,011.50B
MANKIND:NSE Mankind Pharma Ltd

-59.85 (-2.44%)

USD 1,001.78B
AUROPHARMA:NSE Aurobindo Pharma Limited

-13.30 (-0.86%)

USD 893.94B
ALKEM:NSE Alkem Laboratories Limited

-126.55 (-2.04%)

USD 728.19B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-66.95 (-3.91%)

USD 480.90B
AJANTPHARM:NSE Ajanta Pharma Limited

-27.85 (-0.88%)

USD 390.03B

ETFs Containing SUNPHARMA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 48.07% 62% D 74% C
Dividend Return 1.07% 76% C+ 70% C-
Total Return 49.15% 65% D 75% C
Trailing 12 Months  
Capital Gain 62.60% 60% D- 67% D+
Dividend Return 1.18% 78% C+ 67% D+
Total Return 63.78% 62% D 67% D+
Trailing 5 Years  
Capital Gain 353.87% 70% C- 64% D
Dividend Return 10.58% 89% A- 65% D
Total Return 364.45% 70% C- 64% D
Average Annual (5 Year Horizon)  
Capital Gain 33.76% 54% F 47% F
Dividend Return 34.95% 54% F 47% F
Total Return 1.19% 88% B+ 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.35% 94% A 89% A-
Risk Adjusted Return 171.71% 99% N/A 100% F
Market Capitalization 4,371.22B 100% F 99% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.